<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04032509</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.176</org_study_id>
    <secondary_id>2019-A01525-52</secondary_id>
    <nct_id>NCT04032509</nct_id>
  </id_info>
  <brief_title>A Study of Biomarkers of Mild Traumatic BRAIN Injury</brief_title>
  <acronym>BRAINI</acronym>
  <official_title>A Prospective Clinical Study of Biomarkers of Mild Traumatic BRAIN Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with mild traumatic brain injury (mTBI) represent a burden of patients admitted to
      the emergency department. According to the guidelines, a cerebral CT scan is indicated after
      mTBI according to the specific conditions. However, variability exists regarding the respect
      of these CT scan indications, and less than 10% of patients will have visible brain lesions
      on CT scan. Recently, serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal
      Hydrolase-L1 (UCH-L1) biomarkers have shown ability to differentiate normal and abnormal CT
      scan findings after mTBI. These encouraging results prompted us to launch a prospective study
      using automated and quick measurements of GFAP and UCH-L1 biomarkers to validate these
      findings.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of the VIDAS-BTI assay in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and their corresponding lower limit of 95% confidence interval by comparison with brain CT scan findings.</measure>
    <time_frame>12 hours post Traumatic Brain Injury (TBI)</time_frame>
    <description>2 x 5mL blood sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the added value of the two biomarkers measurements to Transcranial Doppler (TCD) performed on admission to detect patients at risk of neurological worsening and patients allowed for a safe return home</measure>
    <time_frame>Admission</time_frame>
    <description>TCD measures at admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the added value of the two biomarkers measurements to Transcranial Doppler (TCD) performed on admission to detect patients at risk of neurological worsening and patients allowed for a safe return home</measure>
    <time_frame>7 days after traumatic brain injury (TBI)</time_frame>
    <description>Neurological status at 1 week after TBI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the added value of the two biomarkers measurements to Transcranial Doppler (TCD) performed on admission to detect patients at risk of neurological worsening and patients allowed for a safe return home</measure>
    <time_frame>7 days after traumatic brain injury (TBI)</time_frame>
    <description>Quality of life after brain injury (QOLIBRI) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination the potential of the two biomarkers in predicting neurological outcome</measure>
    <time_frame>3 month after TBI</time_frame>
    <description>Extended Glasgow Outcome Scale (GOSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the potential of the two biomarkers in predicting neurological outcome</measure>
    <time_frame>3 month after TBI</time_frame>
    <description>Quality of life after brain injury (QOLIBRI) Questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the potential of the two biomarkers in predicting neurological outcome</measure>
    <time_frame>3 month after TBI</time_frame>
    <description>EuroQuol 5 dimensions 5 level questionnaire (EQ-5D-5L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the potential of the two biomarkers in predicting neurological outcome</measure>
    <time_frame>3 month after TBI</time_frame>
    <description>Rivermead Post-concussion symptoms Questionnaire (RPQ)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Mild Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Mild TBI</arm_group_label>
    <description>Mild TBI (GCS 13-15 on admission) within 12 hours after injury</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 x 5 mL blood sample</intervention_name>
    <description>2 x 5 mL blood sample to determine the performance of the automated VIDAS BTI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.</description>
    <arm_group_label>Mild TBI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1600 patients: 1300 patients in France and 300 patients in Spain
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years old (France)

          -  Mild TBI (GCS 13-15 on admission) within 12 hours after injury

          -  Indication of brain CT scan:

               -  neurological focal deficit

               -  anterograde amnesia

               -  Glasgow coma scale score &lt;15 after 2 hours post-TBI

               -  suspicion of vault depression fracture

               -  fracture of the basal skull

               -  persisting nausea, vomiting or headache

               -  post-TBI seizures

               -  Pre-injury treatment with antithrombotic drugs

               -  Loss of consciousness or amnesia with age &gt;65 years, fall &gt;1m or hit pedestrian

               -  Other condition requiring CT scan according to the in-charge physician.

        Exclusion Criteria:

          -  GCS 3-12 on admission

          -  Time of injury unknown

          -  Time to injury exceeding 12 hours

          -  Primary admission for non-traumatic neurological disorder (e.g., stroke, spontaneous
             intracranial hematoma)

          -  Penetrating head trauma

          -  Patient with mechanical ventilation

          -  Pre-injury neurological disorder affecting the assessment of neurological outcome:
             dementia, Parkinson's disease, multiple sclerosis, seizure disorder, brain tumor, and
             history of neurosurgery, stroke or transient ischemic attack (TIA) within the last 30
             days

          -  Venipuncture not feasible

          -  No realization of brain CT-scan

          -  Subject under judiciary control

          -  Pregnant or breastfeeding woman

          -  Subject in exclusion period of another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean françois PAYEN, Pr</last_name>
    <phone>04 76 76 92 88</phone>
    <email>JFPayen@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion RICHARD</last_name>
    <phone>04 76 76 68 29</phone>
    <email>MRichard7@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cordelia ABRIC, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Cordelia ABRIC, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cédric GIL JARDINE, Dr</last_name>
      <email>cedric.giljardine@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Cédric GIL JARDINE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick RAY, Pr</last_name>
      <email>patrick.ray@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick RAY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime MAIGNAN, Dr</last_name>
      <phone>04 76 76 93 93</phone>
      <email>MMaignan@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Maxime MAIGNAN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard HERRIOT - HCL</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent JACQUIN, Dr</last_name>
      <email>laurent.jacquin@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent JACQUIN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Lyon Sud HCL</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion DOUPLAT, Dr</last_name>
      <email>Marion.douplat@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Marion DOUPLAT, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustapha SEBBANE, P</last_name>
      <email>m-sebbane@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Mustapha SEBBANE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel MONTASSIER, Dr</last_name>
      <email>Emmanuel.MONTASSIER@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel MONTASSIER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérémy GUENEZAN, Dr</last_name>
      <email>jeremyguenezan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jérémy GUENEZAN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BALEN Frédéric</last_name>
      <email>balen.f@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>HEBRARD Manon</last_name>
      <email>hebrard.m@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>BALEN Frédéric, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Said LARIBI, Pr</last_name>
      <email>S.LARIBI@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Said LARIBI, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Ouest de Villefranche sur Saône</name>
      <address>
        <city>Villefranche-sur-Saône</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume DURAND, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume DURAND, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Tajo</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Teresa LORCA SERRAITA, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Maria Teresa LORCA SERRAITA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana CASTUERA, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Ana CASTUERA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de 12 Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso LAGARES, Dr</last_name>
      <email>alfonso.lagares@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Alfonso LAGARES, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

